TickerTalks
Browse all tickers →
TickerTalks›$PGEN
PGPGEN

Precigen, Inc.

$PGEN·$2.8B·Biotechnology·Healthcare
$6.38-11.3%YTD+78.5%1Y+83.0%
Price updated 7h ago·X counts updated 5d ago
PGPGEN
$PGENPrecigen, Inc.
$6.39-11.26%45 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PGEN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

45X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $PGEN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 86% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-29

Precigen chatter is bullish. Contributors flag HPV+ cancer data next quarter — valuation could 'more than triple if data are positive (very likely).' CEO reiterating cash-flow positive by year-end and HPV platform validation. Director bought +25k at $7.23. Every pull-down 'a good buy this year' framing. Loud voices constructive on the pipeline + insider signal.

Read what X is saying about $PGEN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PGEN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

Precigen's HPV+ cancer data arrives next quarter with a director backing the truck up — the catalyst stack is specific.

Precigen is a clinical-stage biopharma focused on AdenoVerse immunotherapy platform — the HPV+ cancer indication is the primary near-term driver, with specific director-level conviction buying signaling expectations.

  • The P&L has an unusual revenue acceleration: Q2 revenue grew 6,323% YoY off a tiny base to $55M at a 41% operating margin and $0.06 EPS, with the trailing EPS surprise of 514% being the kind of number that reflects regulatory-approval-driven revenue recognition.
  • The specific insider signal is director buying $25K at $7.23 — modest in dollar terms but concentrated and recent, plus the CEO reiterating cash-flow-positive by year-end and HPV platform validation ahead of HPV+ cancer data next quarter.

At 93% of its 52-week range and 71% above the 200-day going into Nov 12 earnings, the setup is confirmed-breakout tape rather than a coil. A clean HPV+ cancer data readout plus cash-flow-positive confirmation is the trigger for continuation; a soft Q3 revenue print or any safety signal is the invalidation.

Agrees with X sentimentThe bullish HPV+ data catalyst and the specific director buy are both grounded. The 'more than triple if data are positive' framing is aggressive but reflects the asymmetric nature of a small-cap-biotech data event.

What to watch: Nov 12 Q3 earnings and any HPV+ cancer data — cash runway, HPV platform data, cash-flow-positive confirmation, and any named partnership. Positive HPV data plus CFP is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-12 — Q3 earnings

event ahead 30dcatalyst biotech

Read the AI verdict on $PGEN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Precigen develops gene and cell therapies using its ARCUS gene editing and UltraCAR-T platforms targeting cancer and infectious diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PGEN.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $PGEN

Partial — Precigen develops gene and cell therapies using its ARCUS gene editing and UltraCAR-T platforms targeting cancer and infectious diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-27.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-46.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
29.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-498%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.05$-0.01+514.3%
Q1 2026May 13, 2026$-0.02$-0.03+33.3%
Q4 2025Mar 25, 2026$-0.07$-0.10+33.6%
Q3 2025Nov 13, 2025$-1.06$-0.08-1225.0%
Next earningsThu, Nov 12·consensus EPS $0.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$55.0M+6322.7%94.9%41.2%$0.06$-18.2M
Q1 FY26$23.3M+1633.9%87.6%-25.8%$-0.03$-44.1M
Q4 FY25$4.6M+283.6%58.1%-475%$-0.07$-24.1M
Q3 FY25$2.9M+206.6%53.7%-1180%$-1.10$-29.5M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$238.7M$202.1M – $275.3M$0.17$0.10 – $0.252
FY27$443.5M$304.3M – $582.8M$0.64$0.33 – $0.942
FY28$512.1M$429.7M – $594.4M$0.70$0.59 – $0.812
FY29$798.8M$605.5M – $1.1B$1.24$0.85 – $1.771
FY30$982.3M$744.6M – $1.3B$1.50$1.02 – $2.141

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.56%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-12.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+23.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.925-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 26Jeffrey B KindlerDirector185.0K sh$1.4MSellAug 25Phil TennantChief Commercial Officer79.2K sh$594KSellAug 25Rutul R ShahCOO15.3K sh$115KBuyAug 21Nancy H AgeeDirector3.4K sh$25KSellAug 21Rutul R ShahCOO34.7K sh$260KSellAug 6Rutul R ShahCOO32.7K sh$225KSellAug 3Rutul R ShahCOO33.8K sh$220KSellJul 31Thomasian Harry Jr.CFO100.0K sh$606KSellJul 1Thomasian Harry Jr.CFO171.4K sh$948KSellJun 29Rutul R ShahCOO42.9K sh$251K
1–10 of 17
+ 27 other (17 exempts · 5 inkinds · 5 awards) in window

See when $PGEN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 248-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 9 other (2 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysisdefenseworld.net·7d agoPGEN Stock Up More Than 50% in 3 Months: Here's What You Should Knowzacks.com·12d agoComparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)defenseworld.net·12d ago4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hikezacks.com·15d agoPrecigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?zacks.com·16d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $PGEN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport